人才建设

您所在的位置: 首页 - 人才建设 - 师资队伍 - 准聘长聘教师 - 教授 - 协和医院

协和医院

个人简介

赵玉沛,1954年生,籍贯吉林怀德,外科医学家,中国科学院院士,北京协和医院名誉院长,教授,主任医师,博士生导师。1978年考入白求恩医科大学医学系医学专业,1982年获得学士学位。1985年在中国协和医科大学外科学专业攻读硕士学位,从事临床医学专业研究。1993年升为副主任医师。1995年升为主任医师。


主要研究方向

在胰腺肿瘤的转化研究与外科诊治领域深耕多年,对胰腺癌、胰腺内分泌肿瘤及胰腺囊性肿瘤等胰腺疾病的发病机制、早期诊断以及综合治疗等难点问题进行了深入的临床与基础研究,取得了系统性和开创性的成果。


代表性成果

1. Dai M#*, Liu Q#, Xing C#, Tian X#, Cao F#, Tang W#, Lv S, Ma Y, Zhang D, Kleeff J, Yang Y, Liu R, He Q, Li F, Li G, Guo J, Liao Q, Zhao Y*. Early Drain Removal is Safe in Patients With Low or Intermediate Risk of Pancreatic Fistula After Pancreaticoduodenectomy: A Multicenter, Randomized Controlled Trial. Ann Surg. 2022 Feb 1;275(2):e307-e314.

2. Ren B#, Yang J#, Wang C, Yang G, Wang H, Chen Y, Xu R, Fan X, You L*, Zhang T*, Zhao Y*. High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. J Hematol Oncol. 2021 Aug 4;14(1):120.

3. Wang C, Zhang T, Liao Q, Dai M, Guo J, Yang X, Tan W, Lin D*, Wu C*, Zhao Y*. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Protein Cell. 2021 Feb;12(2):128-144.

4. Li Y#, He Y#, Peng J#, Su Z, Li Z, Zhang B, Ma J, Zhuo M, Zou D, Liu X, Liu X, Wang W, Huang D, Xu M, Wang J, Deng H, Xue J, Xie W, Lan X, Chen M, Zhao Y*, Wu W*, David CJ*. Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Nat Cancer. 2021 Jan;2(1):49-65.

5. Yu X#, Hu Y#, Wang Z, He X, Xin S, Li G, Wu S, Zhang Q, Sun H, Lei G, Han W, Xue F, Wang L, Jiang J*, Zhao Y*. Developing a toolbox for identifying when to engage senior surgeons in emergency general surgery: A multicenter cohort study. Int J Surg. 2021 Jan;85:30-39.

6. Hong X#, Qiao S#, Li F, Wang W, Jiang R, Wu H, Chen H, Liu L, Peng J, Wang J, Jia C, Liang X, Dai H, Jiang J, Zhang T, Liao Q, Dai M, Cong L, Han X, Guo D, Liang Z, Li D, Zheng Z, Ye C, Li S, Zhao Y*, Wu K*, Wu W*. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system. Gut. 2020 May;69(5):877-887.

7. Ricciardiello F#, Gang Y#, Palorini R, Li Q, Giampà M, Zhao F, You L, La Ferla B, De Vitto H, Guan W, Gu J, Zhang T*, Zhao Y*, Chiaradonna F*. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. Oncogene. 2020 May;39(20):4103-4117.

8. Zhang S, Chen L, Zhang Z, Zhao Y*. Orphan drug development in China: progress and challenges. Lancet. 2019 Sep 28;394(10204):1127-1128.

9. Peng J#, Sun BF#, Chen CY#, Zhou JY#, Chen YS#, Chen H, Liu L, Huang D, Jiang J, Cui GS, Yang Y, Wang W, Guo D, Dai M, Guo J, Zhang T, Liao Q, Liu Y, Zhao YL, Han DL, Zhao Y*, Yang YG*, Wu W*. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019 Sep;29(9):725-738.

10. Xiong G#, Liu C#, Yang G#, Feng M, Xu J, Zhao F, You L, Zhou L, Zheng L, Hu Y, Wang X*, Zhang T*, Zhao Y*. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. J Hematol Oncol. 2019 Sep 12;12(1):97.